Literature DB >> 19818004

Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization.

Chia-Yang Hsu1, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Jen-Huey Chiang, Pui-Ching Lee, Fa-Yauh Lee, Teh-Ia Huo, Shou-Dong Lee.   

Abstract

BACKGROUND: Ascites is often present in patients with hepatocellular carcinoma (HCC) with cirrhosis. Advanced cirrhosis may predispose to renal dysfunction. Acute renal failure (ARF) may occur after transarterial chemoembolization (TACE) for HCC because of radiocontrast agents. This study aimed to investigate the incidence and risk factors of ARF and prognostic predictors in HCC patients with ascites undergoing TACE.
METHODS: A total of 591 HCC patients receiving TACE were enrolled.
RESULTS: In a mean follow-up duration of 19+/-17 months, 239 (40.4%) patients undergoing TACE died. Ascites, which was present in 91 (15.4%) patients at entry, independently predicted a poor prognosis in the Cox proportional hazard model [risk ratio (RR): 1.71, P=0.002]. Of these, 11 (12.6%) of 87 patients with complete follow-up developed ARF after TACE. Serum albumin level <3.3 g/dl (odds ratio: 7.3, P=0.009) was the only independent risk factor associated with ARF in the logistic regression analysis. ARF (RR: 2.17, P=0.036), alpha-fetoprotein >400 ng/ml (RR: 1.84, P=0.04), multiple tumours (RR: 2.11, P=0.013), tumour size > or = 5 cm (RR: 2.32, P=0.006) and serum sodium level <139 mmol/L (RR: 2.4, P=0.005) were independent poor prognostic predictors for HCC patients with ascites receiving TACE.
CONCLUSIONS: Pre-existing ascites is associated with increased mortality in HCC patients receiving TACE. In HCC patients with ascites, hypoalbuminaemia is associated with the occurrence of post-TACE ARF. Post-TACE ARF is a poor prognostic predictor in this subset of HCC patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19818004     DOI: 10.1111/j.1478-3231.2009.02128.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  18 in total

1.  Risk of acute kidney injury after transarterial chemoembolisation in hepatocellular carcinoma patients: A nationwide population-based cohort study.

Authors:  Bo-Ching Lee; Kao-Lang Liu; Cheng-Li Lin; Chia-Hung Kao
Journal:  Eur Radiol       Date:  2017-06-07       Impact factor: 5.315

2.  Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma.

Authors:  Ya-Ju Tsai; Chia-Yang Hsu; Yi-Hsiang Huang; Chien-Wei Su; Han-Chieh Lin; Rheun-Chuan Lee; Jen-Huey Chiang; Teh-Ia Huo; Shou-Dong Lee
Journal:  Hepatol Int       Date:  2011-04-30       Impact factor: 6.047

3.  Outcome of hepatectomy for hepatocellular carcinoma in patients with renal dysfunction.

Authors:  Takeo Toshima; Ken Shirabe; Shohei Yoshiya; Jun Muto; Toru Ikegami; Tomoharu Yoshizumi; Yoshihiko Maehara
Journal:  HPB (Oxford)       Date:  2012-05       Impact factor: 3.647

4.  Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy.

Authors:  Chia-Yang Hsu; Yun-Hsuan Lee; Yi-Hsiang Huang; Cheng-Yuan Hsia; Chien-Wei Su; Han-Chieh Lin; Rheun-Chuan Lee; Yi-You Chiou; Fa-Yauh Lee; Teh-Ia Huo; Shou-Dong Lee
Journal:  Hepatol Int       Date:  2012-01-08       Impact factor: 6.047

5.  The incidence of contrast-induced nephropathy (CIN) following transarterial chemoembolisation (TACE) in patients with hepatocellular carcinoma (HCC).

Authors:  Katsumi Hayakawa; Masato Tanikake; Toshihiko Kirishima; Naomi Yoshinami; Hiroyuki Shintani; Eiji Yamamoto; Taisuke Morimoto
Journal:  Eur Radiol       Date:  2014-02-13       Impact factor: 5.315

6.  Prognostic factors for acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma.

Authors:  Chunze Zhou; Ruifeng Wang; Yikun Ding; Linan Du; Changlong Hou; Dong Lu; Li Hao; Weifu Lv
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

7.  Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: serum sodium predicts survival.

Authors:  Marco Biolato; Luca Miele; Vittoria Vero; Simona Racco; Carmine Di Stasi; Roberto Iezzi; Andrea Zanché; Maurizio Pompili; Gian Ludovico Rapaccini; Giuseppe La Torre; Antonio Gasbarrini; Antonio Grieco
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

8.  ALBI grade in dialysis patients with hepatocellular carcinoma: prognostic impact and staging strategy.

Authors:  Shu-Yein Ho; Po-Hong Liu; Chia-Yang Hsu; Chih-Chieh Ko; Yi-Hsiang Huang; Chien-Wei Su; Cheng-Yuan Hsia; Rheun-Chuan Lee; Ming-Chih Hou; Teh-Ia Huo
Journal:  J Gastrointest Oncol       Date:  2021-04

9.  Transcatheter arterial chemotherapy with miriplatin for hepatocellular carcinoma patients with chronic renal failure: report of three cases.

Authors:  Norihiro Imai; Kenji Ikeda; Yuya Seko; Yusuke Kawamura; Hitomi Sezaki; Tetsuya Hosaka; Norio Akuta; Masahiro Kobayashi; Satoshi Saitoh; Fumitaka Suzuki; Yoshiyuki Suzuki; Yasuji Arase; Hiromitsu Kumada
Journal:  Gut Liver       Date:  2013-03-14       Impact factor: 4.519

Review 10.  Causal relationship between hypoalbuminemia and acute kidney injury.

Authors:  Christian J Wiedermann; Wolfgang Wiedermann; Michael Joannidis
Journal:  World J Nephrol       Date:  2017-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.